1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 10,300 | 10,900 | 17:55 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:30 | Agomab receives U.S. patent for lung fibrosis drug candidate | 2 | Investing.com | ||
| 12:06 | AgomAb Therapeutics N.V.: Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis | 18 | GlobeNewswire (Europe) | Antwerp, Belgium, March 26, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("'Agomab'"), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent... ► Artikel lesen | |
| 11.03. | Agomab Therapeutics NV - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 05.03. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.03. | Morgan Stanley initiates Agomab Therapeutics stock with overweight rating | 4 | Investing.com | ||
| 03.03. | Morgan Stanley stuft Agomab Therapeutics mit "Overweight" ein und sieht 73 % Kurspotenzial | 2 | Investing.com Deutsch | ||
| 03.03. | JPMorgan initiates Agomab Therapeutics stock at Overweight | 2 | Investing.com | ||
| 03.03. | JPMorgan startet Coverage für Agomab Therapeutics mit "Overweight" | 2 | Investing.com Deutsch | ||
| AGOMAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.02. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 09.02. | AgomAb Therapeutics N.V.: Agomab Announces Closing of Initial Public Offering | 415 | GlobeNewswire (Europe) | ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies... ► Artikel lesen | |
| 06.02. | SpyGlass Pharma surges on public debut; AgomAb falls | 4 | Seeking Alpha | ||
| 06.02. | Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut | 1 | Reuters | ||
| 06.02. | NASDAQ-Debüt: Aktie von Agomab Therapeutics startet unter Ausgabepreis | 1 | Investing.com Deutsch | ||
| 06.02. | Belgian fibrotic disease biotech AgomAb Therapeutics prices IPO at $16 midpoint, raising $200 million | 3 | Renaissance Capital | ||
| 06.02. | Agomab, SpyGlass Pharma head to Nasdaq with IPOs totalling $350M | 1 | FierceBiotech | ||
| 06.02. | Agomab, SpyGlass Pharma bank a combined $350M in biotech IPOs | 1 | BioPharma Dive | ||
| 06.02. | AgomAb Therapeutics N.V.: Agomab Announces Pricing of Initial Public Offering | 348 | GlobeNewswire (Europe) | ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies... ► Artikel lesen | |
| 03.02. | Agomab Therapeutics NV - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 02.02. | AgomAb Therapeutics Prices U.S. IPO At $15-$17 Per ADS | 695 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, said on Monday that it has priced its initial public offering of 12.5 million American... ► Artikel lesen | |
| 29.01. | Belgian biopharma Agomab to raise up to $210M in U.S. IPO | 1 | Seeking Alpha |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,065 | +0,36 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ADMA BIOLOGICS | 7,945 | -17,50 % | ADMA Biologics, Inc.: ADMA Biologics Addresses Misleading Short-Seller Report | RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated... ► Artikel lesen | |
| ARCELLX | 114,50 | -0,03 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme | ||
| EVOTEC | 4,375 | +0,44 % | EQS-News: Evotec SE: Evotec erhält 10 Mio. $ Meilensteinzahlung von Bristol Myers Squibb im Rahmen der Protein-Degradation-Partnerschaft nach Start einer klinischen Studie | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec erhält 10 Mio. $ Meilensteinzahlung von Bristol Myers Squibb im Rahmen der Protein-Degradation-Partnerschaft nach Start einer... ► Artikel lesen | |
| BIONTECH | 76,65 | +0,13 % | Jetzt zuschlagen! Mit BioNTech, Vidac Pharma und Pfizer in die Krebsforschung investieren und Renditen sichern | Die globalen Gesundheitsausgaben explodieren und der Onkologie Sektor verspricht überdurchschnittliche Renditen. Während aufgrund einer immer älter werdenden Bevölkerung die Zahl der Krebsneuerkrankungen... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 39,740 | +11,98 % | Enliven Therapeutics stock price target raised to $56 by H.C. Wainwright | ||
| OCUGEN | 1,694 | -1,14 % | Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment benefit compared to 15% and 22% reductions... ► Artikel lesen | |
| MAZE THERAPEUTICS | 34,860 | +9,43 % | Maze Therapeutics: BTIG bestätigt Kaufempfehlung nach positiven Studiendaten | ||
| CG ONCOLOGY | 66,16 | +0,53 % | UBS raises CG Oncology stock price target to $90 on trial outlook | ||
| SUMMIT THERAPEUTICS | 17,580 | -2,12 % | Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates | ||
| ERASCA | 15,680 | -1,82 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| STRUCTURE THERAPEUTICS | 46,320 | -3,84 % | Wolfe Research initiates Structure Therapeutics stock rating at Peerperform | ||
| STRYKER | 288,70 | +1,87 % | Stryker räumt nun doch Malware-Einsatz ein | ||
| BEAM THERAPEUTICS | 23,580 | +1,86 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,800 | -0,95 % | Raymond James reiterates Strong Buy on Dyne Therapeutics stock |
AGOMAB THERAPEUTICS NV ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,760 (-6,81 %) liegt der Kurs bei 10,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AGOMAB THERAPEUTICS NV ADR finden Sie auf Wallstreet Online.